Výsledky vyhledávání - "Craig W. Davis"

Using weight of evidence to assess degradation potential of UVCB hydrocarbon solvents

Autor: Christopher M, Prosser, Craig W, Davis, Gail E, Bragin, Louise, Camenzuli

Publikováno v: Integrated Environmental Assessment and Management.

Hydrocarbon solvents are a diverse group of petrochemical substances that are known as Unknown or Variable composition, Complex reaction products or Biological materials (UVCBs) and may contain tens of thousands of individual chemical constituents. A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7038e26c67f10ae914d50407ceca70b4
https://doi.org/10.1002/ieam.4731

Zobrazit plný text záznamu

Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials

Autor: Gerard J. Meskill, Craig W. Davis, Donna Zarycranski, Markiyan Doliba, Jean-Charles Schwartz, Jeffrey M. Dayno

Publikováno v: CNS Drugs

Background Pitolisant, a selective histamine 3 receptor antagonist/inverse agonist, is indicated for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The efficacy and safety of pitolisant have been demonstrated in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af53da85d1b0a62b8568257f9be471ee
https://doi.org/10.1007/s40263-021-00886-x

Zobrazit plný text záznamu

Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials

Autor: Nathaniel F. Watson, Jeffrey M Dayno, Ben Vaughn, Donna Zarycranski, Craig W. Davis, Yves Dauvilliers, Jean-Charles Schwartz

Publikováno v: CNS Drugs

Background Pitolisant is approved in the USA and Europe for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. Objective Analyses evaluated the time to onset of clinical response during treatment with pitolisant. Me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbe886b2ef564a766764b0b35d1d14ca
http://europepmc.org/articles/PMC8642365

Zobrazit plný text záznamu

Efficacy of pitolisant in patients with high burden of narcolepsy symptoms: pooled analysis of short-term, placebo-controlled studies

Autor: Ben Vaughn, Lois E. Krahn, Jean Schwartz, Craig W. Davis, Michael J. Thorpy, Ulf Kallweit

Publikováno v: Sleep Medicine. 81:210-217

To evaluate the efficacy of pitolisant, a histamine 3 (HData were pooled from two randomized, placebo-controlled, 7- or 8-week studies of pitolisant (titrated to a potential maximum dose of 35.6 mg/day) in adults with narcolepsy. Analyses included th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5221cd5a5a6772bcf89b542666c5a752
https://doi.org/10.1016/j.sleep.2021.02.037

Zobrazit plný text záznamu

504 Assessment of the Clinical Benefits of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy

Autor: Markiyan Doliba, Donna Zarycranski, Jean-Charles Schwartz, Jeffrey M Dayno, Gerard J Meskill, Craig W. Davis

Publikováno v: Sleep. 44:A198-A199

Introduction When evaluating results of randomized, placebo-controlled trials, the clinical impact of a treatment can be assessed using number needed to treat (NNT; number of patients that need to be treated to achieve a specific outcome for one pers

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::28147c38a01925610efb3c28b0df9f54
https://doi.org/10.1093/sleep/zsab072.503

Zobrazit plný text záznamu

0762 Efficacy Of Pitolisant In Patients With High Burden Of Narcolepsy Symptoms

Autor: Craig W. Davis, Lois E. Krahn, Ulf Kallweit, Ben Vaughn, Michael J. Thorpy

Publikováno v: Sleep. 43:A289-A290

Introduction Recent literature suggests that histamine may play an important role in narcolepsy. This post hoc analysis evaluates the efficacy of pitolisant, a histamine 3 (H3)-receptor antagonist/inverse agonist, in patients with high burden of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6e4b0252b9aca58679a3040ecc1d89d9
https://doi.org/10.1093/sleep/zsaa056.758

Zobrazit plný text záznamu

0768 Time Course Of Improvement In Excessive Daytime Sleepiness And Cataplexy During Treatment With Pitolisant In Patients With Narcolepsy

Autor: A Roy, Jean-Charles Schwartz, Jeffrey M Dayno, Yves Dauvilliers, Craig W. Davis, Ben Vaughn

Publikováno v: Sleep. 43:A291-A292

Introduction This analysis evaluated the efficacy of pitolisant over time in three 7- to 8-week, randomized, placebo-controlled studies of adults with narcolepsy. Methods Patients in all 3 studies (HARMONY-1, HARMONY-1bis, HARMONY-CTP) experienced ex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::56d7b9b257c5461b8c3ac7fc4aae4af3
https://doi.org/10.1093/sleep/zsaa056.764

Zobrazit plný text záznamu

0766 Safety And Tolerability Of Pitolisant In The Treatment Of Adult Patients With Narcolepsy: Final Analysis Of An Open-label, Expanded Access Program In The United States

Autor: Michael J. Thorpy, Albena Patroneva, Craig W. Davis, E D Bauer, Jeffrey M Dayno

Publikováno v: Sleep. 43:A291-A291

Introduction Pitolisant Expanded Access Clinical Evaluation (PEACE) provided adult patients with narcolepsy access to treatment with pitolisant while it was an investigational medication in the United States. Methods Pitolisant was titrated to 35.6 m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e97c79a3358782195b68f0f1083087a
https://doi.org/10.1093/sleep/zsaa056.762

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání